Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial

• Published in: Critical care (London, England) England), 2008-01, Vol.12 (5), p.R120-R120, Article R120
• Main Authors: De La Rosa, Gisela Del Carmen, Donado, Jorge Hernando, Restrepo, Alvaro Humberto, Quintero, Alvaro Mauricio, González, Luis Gabriel, Saldarriaga, Nora Elena, Bedoya, Marisol, Toro, Juan Manuel, Velásquez, Jorge Byron, Valencia, Juan Carlos, Arango, Clara Maria, Aleman, Pablo Henrique, Vasquez, Esdras Martin, Chavarriaga, Juan Carlos, Yepes, Andrés, Pulido, William, Cadavid, Carlos Alberto
• Format: Article
• Language: English
• Subjects: Adult; Aged; Blood Glucose - metabolism; Care and treatment; Complications and side effects; Critical Care - methods; Critical Care - standards; Critically ill; Female; Glycemic Index - physiology; Health aspects; Hospitalization; Humans; Hyperglycemia; Insulin; Insulin - blood; Intensive Care Units - standards; Male; Middle Aged; Prospective Studies; Risk factors
• ISSN: 1364-8535; 1466-609X; 1364-8535
• DOI: 10.1186/cc7017

Critically ill patients can develop hyperglycaemia even if they do not have diabetes. Intensive insulin therapy decreases morbidity and mortality rates in patients in a surgical intensive care unit (ICU) and decreases morbidity in patients in a medical ICU. The effect of this therapy on patients in a mixed medical/surgical ICU is unknown. Our goal was to assess whether the effect of intensive insulin therapy, compared with standard therapy, decreases morbidity and mortality in patients hospitalised in a mixed ICU. This is a prospective, randomised, non-blinded, single-centre clinical trial in a medical/surgical ICU. Patients were randomly assigned to receive either intensive insulin therapy to maintain glucose levels between 80 and 110 mg/dl (4.4 to 6.1 mmol/l) or standard insulin therapy to maintain glucose levels between 180 and 200 mg/dl (10 and 11.1 mmol/l). The primary end point was mortality at 28 days. Over a period of 30 months, 504 patients were enrolled. The 28-day mortality rate was 32.4% (81 of 250) in the standard insulin therapy group and 36.6% (93 of 254) in the intensive insulin therapy group (Relative Risk [RR]: 1.1; 95% confidence interval [CI]: 0.85 to 1.42). The ICU mortality in the standard insulin therapy group was 31.2% (78 of 250) and 33.1% (84 of 254) in the intensive insulin therapy group (RR: 1.06; 95%CI: 0.82 to 1.36). There was no statistically significant reduction in the rate of ICU-acquired infections: 33.2% in the standard insulin therapy group compared with 27.17% in the intensive insulin therapy group (RR: 0.82; 95%CI: 0.63 to 1.07). The rate of hypoglycaemia (< or = 40 mg/dl) was 1.7% in the standard insulin therapy group and 8.5% in the intensive insulin therapy group (RR: 5.04; 95% CI: 1.20 to 21.12). IIT used to maintain glucose levels within normal limits did not reduce morbidity or mortality of patients admitted to a mixed medical/surgical ICU. Furthermore, this therapy increased the risk of hypoglycaemia. clinicaltrials.gov Identifiers: 4374-04-13031; 094-2 in 000966421.